Identifying genetic markers for skin lymphomas
Official title: Genomic biomarkers for cutaneous T-cell Lymphoma
Funded at Sloan-Kettering Inst Can Research · NIH-10812990 · Data updated 2026-11-12
This study is looking at skin cancers called cutaneous T-cell lymphomas to find genetic clues that can help doctors diagnose and treat these conditions earlier and more effectively, especially for patients with specific types like mycosis fungoides and Sezary syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | October 1, 2022 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $327,323 |
| NIH project number | 5R01CA238552-06 |
| Project ID | NIH-10812990 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with cutaneous T-cell lymphomas, particularly those experiencing delays in diagnosis or with early-stage disease.
✕Less likely to help
Patients with non-cutaneous forms of lymphoma or those who do not have a confirmed diagnosis of CTCL may not benefit from this research.
What this research studies
This research focuses on understanding cutaneous T-cell lymphomas (CTCL), which are aggressive skin cancers with a high mortality rate. The study aims to identify genomic biomarkers that can help in the early diagnosis and prognosis of CTCL, particularly for subtypes like mycosis fungoides and Sezary syndrome. By analyzing genetic alterations in these tumors, the research seeks to improve diagnostic accuracy and develop targeted therapies, ultimately enhancing patient outcomes. The approach involves detailed genetic analysis and clinical assessments to correlate findings with patient health.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and more effective treatment options for patients with aggressive skin lymphomas.
How similar studies have gone: Previous research has shown promise in identifying genetic markers for other types of cancers, suggesting potential success for this novel approach in CTCL.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Lim, Megan S. — Sloan-Kettering Inst Can Research
- Study coordinator: Lim, Megan S.
Related research
Other NIH-funded projects on the same topics.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
Understanding how IL-15 affects T-cell lymphoma in the skin
This research explores how a specific signal, called IL-15, helps T-cell lymphoma cells move to and grow in the skin, aiming to find new ways to help patients with this condition.
-
New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma
This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.
-
Investigating how Staphylococcus aureus affects skin cancer development
This study is looking at how a common skin bacteria called Staphylococcus aureus might affect the growth of Cutaneous T-cell lymphomas (CTCL), a type of skin cancer, by examining the bacteria found on patients' skin to find new ways to understand and treat the disease.
-
Understanding how gene regulation affects cutaneous T cell lymphoma
This study is looking at how changes in DNA can affect a type of skin cancer called cutaneous T cell lymphoma, especially a severe form known as Sezary syndrome, to help find better ways to diagnose and treat it, and patients can help us learn more about how these changes might impact their treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.